RxDoctor Payments Data

Niraj Nathan, MD

Glaucoma Specialist · Buford, GANPI 1588920060

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Alcon at 30.6% of the total. Reporting peaked in 2023 at $849 and has fallen 87.4% since, to $107 in 2025.

$2,232in general payments, 2019–2025

Across 57 payments — averaging $39.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$683
  • Sight Sciences, Inc.$487
  • AbbVie$359
  • Bausch & Lomb Americas Inc.$166
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$131
  • Johnson & Johnson Surgical Vision, Inc.$130
  • plus $275 from 8 others

What the payments were for

  • Food & beverage$2,09894%
  • Education$1336%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$193,267
Medicare patients
391
Services billed
1,581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost110$55,138
RocklatanNetarsudil Mesylat/Latanoprost63$32,043
RestasisCyclosporine36$24,805
CombiganBrimonidine Tartrate/Timolol47$19,607
SimbrinzaBrinzolamide/Brimonidine Tart51$13,110
RhopressaNetarsudil Mesylate30$12,513
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol44$11,921
VyzultaLatanoprostene Bunod18$7,514
IlevroNepafenac17$6,841
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat368$6,729
Latanoprost574$6,710
Prednisolone Acetate132$6,324
Brinzolamide20$5,798
Travoprost23$4,392
Brimonidine Tartrate216$4,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$359$99,550193 claims
AlconSimbrinza$683$13,11051 claims
Bausch & Lomb Americas Inc.Vyzulta$166$7,51418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Buford

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →